EVQ 218
Alternative Names: EVQ-218Latest Information Update: 03 Oct 2024
Price :
$50 *
At a glance
- Originator EVOQ Bio
- Class Antibacterials; Antifibrotics; Antifungals; Antituberculars; Small molecules
- Mechanism of Action Bacterial biofilm inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cystic fibrosis; Mycoses; Pneumonia; Tuberculosis
Most Recent Events
- 27 Sep 2024 Pharmacodynamics data from preclinical studies in Cystic fibrosis released by EVOQ Bio
- 15 May 2024 EVOQ Bio completes pre-investigational new drug (pre-IND) meeting with US FDA for EVQ 218 for Cystic fibrosis
- 15 May 2024 Pharmacodynamics and adverse events data from preclinical trial in Cystic fibrosis released by EVOQ Bio